Kevin Patrick Danahy insider trades: Pulse Biosciences (PLSE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kevin reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | PLSE | ↓ Sell | 60,000 | $23.51 | $1.4M | Direct | Feb 17, 2026 (0d) |
| Feb 11, 2026 | PLSE | ↓ Sell | 60,000 | $23.39 | $1.4M | Direct | Feb 11, 2026 (0d) |
| Oct 2, 2025 | PLSE | ↓ Sell | 4,600 | $18.53 | $85K | Direct | Oct 7, 2025 (5d) |
| Sep 19, 2025 | PLSE | ↓ Sell | 20,400 | $18.49 | $377K | Direct | Sep 22, 2025 (3d) |
| Nov 16, 2023 | PLSE | ↑ Buy | 5,393 | $6.52 | $35K | Direct | Nov 17, 2023 (1d) |
| Sep 30, 2022 | PLSE | ↑ Buy | 6,500 | $2.30 | $15K | Direct | Oct 3, 2022 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PLSE insiders
Open-market trades in the last 12 months
About Kevin Patrick Danahy's insider trades
Kevin Patrick Danahy is Chief Commercial Officer at Pulse Biosciences (PLSE). Since Sep 30, 2022, Kevin has reported 2 open-market purchases worth $50K and 4 sales worth $3.3M on SEC Form 4. In the last 12 months: 2 sales ($2.8M).
Their filings also include grants and awards (6 filings), option exercises (5 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PLSE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.